vs
Medpace Holdings, Inc.（MEDP）とUNITED THERAPEUTICS Corp（UTHR）の財務データ比較。上の社名をクリックして会社を切り替えられます
UNITED THERAPEUTICS Corpの直近四半期売上が大きい（$790.2M vs $708.5M、Medpace Holdings, Inc.の約1.1倍）。UNITED THERAPEUTICS Corpの純利益率が高く（46.1% vs 19.1%、差は27.0%）。Medpace Holdings, Inc.の前年同期比売上増加率が高い（32.0% vs 7.4%）。Medpace Holdings, Inc.の直近四半期フリーキャッシュフローが多い（$188.1M vs $173.3M）。過去8四半期でMedpace Holdings, Inc.の売上複合成長率が高い（17.7% vs 8.0%）
Medpace Holdings, Inc.は米国オハイオ州シンシナティに本社を置くグローバルな臨床研究機関（CRO）で、従業員数は約6,000人です。フルサービス体制を採用し、グローバル中央検査室、画像コアラボ、生物分析検査室サービスを提供するほか、本社敷地内に第I相臨床試験部門を設けています。
ユナイテッド・セラピューティクスは米国のバイオテクノロジー企業で、異種移植を含む臓器移植関連の医薬品や技術を開発しています。主力製品の多くは肺疾患治療や臓器製造分野向けで、メリーランド州とノースカロライナ州に2つの本社を置き、米国各地やカナダにも拠点を構えています。
MEDP vs UTHR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $708.5M | $790.2M |
| 純利益 | $135.1M | $364.3M |
| 粗利率 | — | 86.9% |
| 営業利益率 | 21.6% | 45.1% |
| 純利益率 | 19.1% | 46.1% |
| 売上前年比 | 32.0% | 7.4% |
| 純利益前年比 | 15.5% | 20.9% |
| EPS（希薄化後） | $4.65 | $7.66 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $708.5M | $790.2M | ||
| Q3 25 | $659.9M | $799.5M | ||
| Q2 25 | $603.3M | $798.6M | ||
| Q1 25 | $558.6M | $794.4M | ||
| Q4 24 | $536.6M | $735.9M | ||
| Q3 24 | $533.3M | $748.9M | ||
| Q2 24 | $528.1M | $714.9M | ||
| Q1 24 | $511.0M | $677.7M |
| Q4 25 | $135.1M | $364.3M | ||
| Q3 25 | $111.1M | $338.7M | ||
| Q2 25 | $90.3M | $309.5M | ||
| Q1 25 | $114.6M | $322.2M | ||
| Q4 24 | $117.0M | $301.3M | ||
| Q3 24 | $96.4M | $309.1M | ||
| Q2 24 | $88.4M | $278.1M | ||
| Q1 24 | $102.6M | $306.6M |
| Q4 25 | — | 86.9% | ||
| Q3 25 | — | 87.4% | ||
| Q2 25 | — | 89.0% | ||
| Q1 25 | — | 88.4% | ||
| Q4 24 | — | 89.7% | ||
| Q3 24 | — | 88.9% | ||
| Q2 24 | — | 89.1% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | 21.6% | 45.1% | ||
| Q3 25 | 21.5% | 48.6% | ||
| Q2 25 | 20.9% | 45.6% | ||
| Q1 25 | 20.3% | 48.2% | ||
| Q4 24 | 23.4% | 48.6% | ||
| Q3 24 | 21.1% | 45.8% | ||
| Q2 24 | 19.9% | 44.7% | ||
| Q1 24 | 20.4% | 52.6% |
| Q4 25 | 19.1% | 46.1% | ||
| Q3 25 | 16.8% | 42.4% | ||
| Q2 25 | 15.0% | 38.8% | ||
| Q1 25 | 20.5% | 40.6% | ||
| Q4 24 | 21.8% | 40.9% | ||
| Q3 24 | 18.1% | 41.3% | ||
| Q2 24 | 16.7% | 38.9% | ||
| Q1 24 | 20.1% | 45.2% |
| Q4 25 | $4.65 | $7.66 | ||
| Q3 25 | $3.86 | $7.16 | ||
| Q2 25 | $3.10 | $6.41 | ||
| Q1 25 | $3.67 | $6.63 | ||
| Q4 24 | $3.67 | $6.23 | ||
| Q3 24 | $3.01 | $6.39 | ||
| Q2 24 | $2.75 | $5.85 | ||
| Q1 24 | $3.20 | $6.17 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $497.0M | $2.9B |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $459.1M | $7.1B |
| 総資産 | $2.0B | $7.9B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $497.0M | $2.9B | ||
| Q3 25 | $285.4M | $2.8B | ||
| Q2 25 | $46.3M | $3.0B | ||
| Q1 25 | $441.4M | $3.3B | ||
| Q4 24 | $669.4M | $3.3B | ||
| Q3 24 | $656.9M | $3.3B | ||
| Q2 24 | $510.9M | $3.0B | ||
| Q1 24 | $407.0M | $2.7B |
| Q4 25 | $459.1M | $7.1B | ||
| Q3 25 | $293.6M | $6.6B | ||
| Q2 25 | $172.4M | $7.2B | ||
| Q1 25 | $593.6M | $6.8B | ||
| Q4 24 | $825.5M | $6.4B | ||
| Q3 24 | $881.4M | $6.1B | ||
| Q2 24 | $763.6M | $5.7B | ||
| Q1 24 | $671.5M | $5.3B |
| Q4 25 | $2.0B | $7.9B | ||
| Q3 25 | $1.8B | $7.4B | ||
| Q2 25 | $1.6B | $7.9B | ||
| Q1 25 | $1.9B | $7.7B | ||
| Q4 24 | $2.1B | $7.4B | ||
| Q3 24 | $2.1B | $7.1B | ||
| Q2 24 | $1.9B | $6.7B | ||
| Q1 24 | $1.8B | $6.5B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $192.7M | $346.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $188.1M | $173.3M |
| FCFマージンFCF / 売上 | 26.6% | 21.9% |
| 設備投資強度設備投資 / 売上 | 0.6% | 21.9% |
| キャッシュ転換率営業CF / 純利益 | 1.43× | 0.95× |
| 直近12ヶ月FCF直近4四半期 | $681.9M | $1.0B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $192.7M | $346.2M | ||
| Q3 25 | $246.2M | $562.1M | ||
| Q2 25 | $148.5M | $191.7M | ||
| Q1 25 | $125.8M | $461.2M | ||
| Q4 24 | $190.7M | $341.2M | ||
| Q3 24 | $149.1M | $377.2M | ||
| Q2 24 | $116.4M | $232.2M | ||
| Q1 24 | $152.7M | $376.5M |
| Q4 25 | $188.1M | $173.3M | ||
| Q3 25 | $235.5M | $351.6M | ||
| Q2 25 | $142.4M | $129.5M | ||
| Q1 25 | $115.8M | $386.3M | ||
| Q4 24 | $183.0M | $254.5M | ||
| Q3 24 | $138.5M | $300.7M | ||
| Q2 24 | $103.5M | $187.1M | ||
| Q1 24 | $147.2M | $338.3M |
| Q4 25 | 26.6% | 21.9% | ||
| Q3 25 | 35.7% | 44.0% | ||
| Q2 25 | 23.6% | 16.2% | ||
| Q1 25 | 20.7% | 48.6% | ||
| Q4 24 | 34.1% | 34.6% | ||
| Q3 24 | 26.0% | 40.2% | ||
| Q2 24 | 19.6% | 26.2% | ||
| Q1 24 | 28.8% | 49.9% |
| Q4 25 | 0.6% | 21.9% | ||
| Q3 25 | 1.6% | 26.3% | ||
| Q2 25 | 1.0% | 7.8% | ||
| Q1 25 | 1.8% | 9.4% | ||
| Q4 24 | 1.4% | 11.8% | ||
| Q3 24 | 2.0% | 10.2% | ||
| Q2 24 | 2.4% | 6.3% | ||
| Q1 24 | 1.1% | 5.6% |
| Q4 25 | 1.43× | 0.95× | ||
| Q3 25 | 2.22× | 1.66× | ||
| Q2 25 | 1.65× | 0.62× | ||
| Q1 25 | 1.10× | 1.43× | ||
| Q4 24 | 1.63× | 1.13× | ||
| Q3 24 | 1.55× | 1.22× | ||
| Q2 24 | 1.32× | 0.83× | ||
| Q1 24 | 1.49× | 1.23× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
